Phathom Pharmaceuticals (PHAT) 10-K 30 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Entity Registrant Name	PHATHOM PHARMACEUTICALS, INC.
Entity Central Index Key	0001783183
Entity Tax Identification Number	82-4151574
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-39094
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	100 Campus Drive
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Florham Park
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07932
City Area Code	877
Local Phone Number	742-8466
Entity Common Stock, Shares Outstanding		31,321,613
Entity Public Float			$ 552.3
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PHAT
Security Exchange Name	NASDAQ
Documents Incorporated by Reference	Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 287,496	$ 243,765
Prepaid expenses and other current assets (including related party amounts of $82 and $0, respectively)	3,872	11,836
Total current assets	291,368	255,601
Property, plant and equipment, net	986	463
Operating lease right-of-use assets	2,373	933
Other long-term assets	384	181
Total assets	295,111	257,178
Current liabilities:
Accounts payable (including related party amounts of $173 and $200, respectively)	16,782	699
Accrued clinical trial expenses	19,997
Accrued expenses (including related party amounts of $734 and $308, respectively)	10,606	2,319
Accrued interest	312	156
Current portion of long-term debt	7,353
Operating lease liabilities, current	474	161
Warrant liabilities		413
Total current liabilities	55,524	3,748
Long-term debt, net of discount	39,634	22,777
Operating lease liabilities	1,557	635
Other long-term liabilities	4,125	2,063
Total liabilities	100,840	29,223
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019
Common stock, $0.0001 par value; authorized shares —400,000,000 at December 31, 2020 and 2019; issued shares— 31,262,769 and 28,964,506 at December 31, 2020 and 2019, respectively; outstanding shares— 28,516,010 and 24,728,258 at December 31, 2020 and 2019, respectively	3	2
Additional paid-in capital	579,755	484,372
Accumulated deficit	(385,487)	(256,419)
Total stockholders’ equity	194,271	227,955
Total liabilities and stockholders’ equity	$ 295,111	$ 257,178

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Prepaid expenses and other current assets, related parties	$ 82	$ 0
Accounts payable, related parties	173	200
Accrued expenses, related parties	$ 734	$ 308
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	40,000,000	40,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	400,000,000	400,000,000
Common stock, issued shares	31,262,769	28,964,506
Common stock, outstanding shares	28,516,010	24,728,258

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development (includes related party amounts of $2,812 and $1,243, respectively)	$ 98,148	$ 20,374
In-process research and development		78,897
General and administrative (includes related party amounts of $157 and $312, respectively)	27,517	6,944
Total operating expenses	125,665	106,215
Loss from operations	(125,665)	(106,215)
Other income (expense):
Interest income	1,091	1,089
Interest expense (includes related party amounts of $0 and $(590), respectively)	(4,581)	(4,177)
Change in fair value of warrant liabilities (includes related party amounts of $0 and $(96,278), respectively)	95	(96,272)
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $(10,941), respectively)		(49,546)
Other income (expense)	(8)	(10)
Total other income (expense)	(3,403)	(148,916)
Net loss and comprehensive loss	$ (129,068)	$ (255,131)
Net loss per share, basic and diluted	$ (3.88)	$ (22.45)
Weighted-average shares of common stock outstanding, basic and diluted	33,228,158	11,366,916

Statements of Operations and _2

Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Research and development expenses, related party	$ 2,812	$ 1,243
General and administrative expenses, related party	157	312
Interest expense, related party	0	(590)
Change in fair value of warrant liabilities, related party	0	(96,278)
Change in fair value of convertible promissory notes, related party	$ 0	$ (10,941)

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Takeda License	Underwritten Public Offering	IPO	Common Stock	Common StockFrazier	Common StockTakeda License	Common StockUnderwritten Public Offering	Common StockIPO	Additional Paid-in Capital	Additional Paid-in CapitalTakeda License	Additional Paid-in CapitalUnderwritten Public Offering	Additional Paid-in CapitalIPO	Accumulated Deficit
Beginning balance at Dec. 31, 2018	$ (1,286)				$ 0					$ 2				$ (1,288)
Beginning balance, shares at Dec. 31, 2018					0
Merger of entities under common control into the Company, shares					6,760,334
Vesting restrictions placed on previously issued and outstanding common stock, shares					(3,373,408)
Issuance of common stock		$ 5,885		$ 191,472					$ 1		$ 5,885		$ 191,471
Issuance of common stock, shares						1,491,072	1,084,000		10,997,630
Conversion of warrant liability into equity	144,172									144,172
Conversion of May 2019 Notes and accrued interest into common shares	$ 142,437				$ 1					142,436
Conversion of May 2019 Notes and accrued interest into common shares, shares					6,107,918
Issuance of common stock from exercise of stock options, shares	0
Vesting of restricted shares, shares					1,660,712
Stock-based compensation	$ 406									406
Net loss	(255,131)													(255,131)
Ending balance at Dec. 31, 2019	$ 227,955				$ 2					484,372				(256,419)
Ending balance, shares at Dec. 31, 2019	24,728,258				24,728,258
Issuance of common stock			$ 88,596									$ 88,596
Issuance of common stock, shares								2,250,000
Conversion of warrant liability into equity	$ 318									318
Issuance of common stock from exercise of stock options	629									629
Issuance of common stock from exercise of stock options, shares					48,263
Vesting of restricted shares	1				$ 1
Vesting of restricted shares, shares					1,489,489
Stock-based compensation	5,840									5,840
Net loss	(129,068)													(129,068)
Ending balance at Dec. 31, 2020	$ 194,271				$ 3					$ 579,755				$ (385,487)
Ending balance, shares at Dec. 31, 2020	28,516,010				28,516,010

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (129,068)	$ (255,131)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	323	8
Stock-based compensation	5,840	406
Amortization of debt discount	1,273	409
Acquired in-process research and development		78,897
Non-cash interest expense (includes related party amounts of $0 and $590, respectively)		2,605
Change in fair value of warrant liabilities (includes related party amounts of $0 and $96,278, respectively)	(95)	96,272
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $10,941, respectively)		49,546
Other	322
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (includes related party amounts of $(82) and $19, respectively)	7,963	(11,813)
Accounts payable and accrued expenses (includes related party amounts of $399 and $460, respectively)	24,009	2,265
Accrued clinical trial expenses	19,997
Accrued interest	156	156
Operating right-of-use asset and lease liabilities	(205)	51
Other long-term assets	(203)	(181)
Net cash used in operating activities	(69,688)	(36,510)
Cash flows from investing activities
Cash paid for purchased in-process research and development		(25,118)
Cash paid for property, plant and equipment	(1,040)	(132)
Net cash used in investing activities	(1,040)	(25,250)
Cash flows from financing activities
Proceeds from initial public offering, net of issuance costs		191,472
Proceeds from underwritten public offering, net	88,830
Proceeds from issuance of common stock from exercise of stock options	629
Proceeds from issuance of convertible promissory notes		88,324
Net proceeds from issuance of long-term debt	25,000	24,850
Net cash provided by financing activities	114,459	304,646
Net increase in cash and cash equivalents	43,731	242,886
Cash and cash equivalents – beginning of period	243,765	879
Cash and cash equivalents – end of period	287,496	243,765
Supplemental disclosure of cash flow information
Interest paid	3,464	1,007
Supplemental disclosure of noncash investing and financing activities
Exchange of accrued interest for convertible promissory notes		27
Issuance of common stock warrants in connection with long-term debt		419
Property and equipment purchases included in accounts payable and accrued expenses	145	339
Final interest payment fee	2,063	2,063
Operating lease liabilities arising from obtaining right-of-use assets	1,396	796
Conversion of convertible promissory notes and accrued interest into common shares		142,437
Underwritten public offering costs included in accounts payable and accrued expenses	234
Takeda Warrants
Supplemental disclosure of noncash investing and financing activities
Conversion of Lender Warrants into Equity		144,172
Lender Warrants
Supplemental disclosure of noncash investing and financing activities
Conversion of Lender Warrants into Equity	$ 318
Takeda License
Supplemental disclosure of noncash investing and financing activities
Issuance of Takeda Warrants in connection with Takeda License		47,894
Issuance of common stock in connection with Takeda License		$ 5,885

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Cash Flows [Abstract]
Non-cash interest expense, related party	$ 0	$ 590
Change in fair value of warrant liabilities related party	0	96,278
Change in fair value of convertible promissory notes related party	0	10,941
Related parties prepaid expenses and other assets current	(82)	19
Related parties accounts payable and accrued expenses	$ 399	$ 460

Organization, Basis of Presenta

Organization, Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization, Basis of Presentation and Summary of Significant Accounting Policies	1. Organization, Basis of Presentation and Summary of Significant Accounting Policies Organization Phathom Pharmaceuticals, Inc. (the “Company” or “Phathom”) was incorporated in the state of Delaware in January 2018 under the name North Bridge IV, Inc. On March 13, 2019, the Company changed its name to Phathom Pharmaceuticals, Inc. and merged with YamadaCo IIA, Inc. (“YamadaCo”), a Delaware corporation formed in September 2017, with Phathom being the surviving entity (the “Merger”). All activities of YamadaCo prior to 2018 related to formation and were insignificant. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Basis of Presentation The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The accompanying financial statements include the accounts of the Company (the receiving entity) and YamadaCo, prior to the Merger. The Company and YamadaCo were entities under the common control of Frazier Life Sciences IX, L.P. (“Frazier”) as a result of, among other things, Frazier’s; (i) ownership of a majority of the outstanding capital stock of both companies, (ii) financing of both companies, (iii) control of the board of directors of both companies, and (iv) management of both companies. Both the Company and YamadaCo were formed for the purpose of identifying potential assets around which to form an operating company. As the merged entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company and YamadaCo as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions have been eliminated. Liquidity and Capital Resources From inception to December 31, 2020, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2020, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, and the sale of 10,997,630 shares of common stock for net proceeds of approximately $191.5 million in its 2019 IPO. Additionally, in December 2020, the Company raised net proceeds of $88.6 million from the sale of 2,250,000 shares of common stock at a public offering price of $39.48 per share after deducting underwriting discounts and commissions, and an additional $0.2 million in offering costs. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, (if needed), that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. Use of Estimates The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions. Fair Value Option As permitted under Accounting Standards Codification (“ASC”) 825, Financial Instruments Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities and convertible promissory notes are recorded at fair value on a recurring basis. The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Liabilities measured at fair value on a recurring basis are as follows (in thousands): The warrant liabilities consist of warrants (the “Lender Warrants”) issued in connection with a loan and security agreement (the “Loan Agreement”) for commercial bank debt (see Note 7). The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands): Warrant Liabilities Convertible Promissory Notes Balance at December 31, 2018 $ — $ 1,950 Issuance of convertible promissory notes — 90,750 Exchange of convertible promissory notes (Note 4) — (2,399 ) Issuance of warrants 48,313 — Change in fair value 96,272 49,546 Reclassification of Takeda Warrants into Equity (Note 4) (144,172 ) — Conversion of May 2019 Notes into common shares upon IPO (Note 5) — (139,847 ) Balance at December 31, 2019 413 — Change in fair value (95 ) — Reclassification of Lender Warrants into equity (Note 7) (318 ) — Balance at December 31, 2020 $ — $ — Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Property, Plant, and Equipment, Net Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over two to three years. Furniture and fixtures are depreciated over three years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through December 31, 2020. Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components. Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials. The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. General and Administrative Expenses General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions. Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur. The Company also maintains an employee stock purchase program ("ESPP") under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss was the same as its reported net loss for all periods presented. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. Net Loss Per Share For the year ended December 31, 2019, the net loss per share was recast to include in the numerator the net losses of both the Company and YamadaCo and include in the denominator the weighted-average outstanding shares of both the Company and YamadaCo. Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included 7,588,000 shares of common stock under its warrant (the “Takeda Warrant”) issued to Takeda Pharmaceutical Company Limited (“Takeda”) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company’s IPO because the Takeda Warrant is exercisable for little consideration. For the years ended December 31, 2020 and 2019, the Company has excluded weighted-average unvested shares of 3,424,676 and 3,593,034, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options, warrants and convertible promissory notes. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize, as an allowance, its estimate of expected credit losses. ASU 2016-13 is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance effective January 1, 2020, and the adoption did not have a material impact on the Company's financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, modifies and adds disclosure requirements on fair value measurements. The standard is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance effective January 1, 2020, and the adoption did not have a material impact on the Company’s financial statements. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company does not expect the adoption of ASU 2019-12 will have a significant impact on its financial statements.

Balance Sheet Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	2. Balance Sheet Details Property, Plant and Equipment, net Property, plant and equipment, net, consist of the following (in thousands): Years Ended December 31, 2020 2019 Computer equipment and software $ 516 $ 152 Furniture and fixtures 747 306 Leasehold improvements 54 13 1,317 471 Less: accumulated depreciation (331 ) (8 ) Total property, plant and equipment, net $ 986 $ 463 Depreciation expense for the years ended December 31, 2020 and 2019 was approximately $0.3 million and $8,000, respectively. Accrued Expenses Accrued expenses consist of the following (in thousands): Years Ended December 31, 2020 2019 Accrued research and development expenses $ 4,864 $ 384 Accrued compensation expenses 4,587 1,052 Accrued professional & consulting expenses 1,123 478 Accrued other 32 405 Total accrued expenses $ 10,606 $ 2,319

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Frazier is a principal stockholder of the Company and is represented on the Company’s board of directors. The Company has conducted operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office space to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with the operations of the Company and charged the Company for those expenses. As of December 31, 2020 and 2019, the Company had outstanding accounts payable and accrued expenses due to Frazier in the amount of $35,000 and $0.1 million, Frazier is a principal stockholder in PCI Pharma Services (“PCI”). In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2020 and 2019, the Company had $0.4 million and $0.3 million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2020 and 2019, the Company incurred $2.3 million and $1.1 million, respectively, of expenses related to services performed by PCI. Mountain Field LLC (“Mountain Field”) is an entity owned by the chairman of the Company’s board of directors. During 2019, the Company charged Mountain Field for certain rent and payroll related expenses. These shared expenses were allocated based on usage of the related facilities and time incurred by personnel. For the year ended December 31, 2019, the Company charged Mountain Field $0.1 million Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company’s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. As of December 31, 2020 and 2019, the Company had $22,000 and $0.1 million, respectively, in outstanding accounts payable and accrued expenses related to these supply services. For the year ended December 31, 2019, the Company incurred $0.1 million of expenses related to services performed by Takeda. The Company did not have any such expenses incurred for the year ended December 31, 2020. On May 5, 2020, the Company entered into a Commercial Supply Agreement (the “Commercial Supply Agreement”) with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply the Company with and the Company has agreed to purchase from Takeda certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of two years from the date the Company places an order for bulk drug product for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. As of December 31, 2020, the Company had $0.2 million in outstanding accounts payable and accrued expenses related to these bulk drug product costs. For the year ended December 31, 2020, the Company incurred $0.3 million of expenses related to the Commercial Supply Agreement. The Company has a remaining minimum purchase obligation of approximately $2.2 million related to this agreement. In connection with the Takeda License, the Company entered into a temporary services agreement (the “Temporary Services Agreement”) with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2020, the Company had $0.2 million in outstanding accounts payable and accrued expenses related to these temporary services. For the year ended December 31, 2020 the company incurred $0.2 million of expenses related to the temporary services performed by Takeda.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies License Agreement On May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe (the “Takeda License”). The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents. In consideration of the Takeda License, the Company (i) paid Takeda $25.0 million in cash, (ii) issued Takeda 1,084,000 shares of its common stock at a fair value of $5.9 million, (iii) issued the Takeda Warrant to purchase 7,588,000 shares of its common stock at an exercise price of $0.00004613 per share at an initial fair value of $47.9 million, and (iv) issued a right to receive an additional common stock warrant (the “Takeda Warrant Right”) should Takeda’s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company’s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and no additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $250.0 million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Company incurred $0.1 million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $0.00004613 per share, expires on May 7, 2029 and became exercisable upon the consummation of the IPO. Following the October 11, 2019 increase in the Company’s authorized shares of common stock to 50,000,000, the Company recorded a non-cash charge related to the final fair value adjustment of the Takeda Warrants and reclassified the full balance of $144.2 million from warrant liabilities to additional paid-in capital. Purchase Commitments In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $3.8 million in the first 24-month period following the launch of the final product. The Company has not incurred any expenses under the agreement during the year ended December 31, 2020. Contingencies In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Promissory Notes	5. Convertible Promissory Notes Frazier Convertible Note Financing From January 2018 to April 2019, the Company issued convertible promissory notes to Frazier (the “Frazier Notes”) for an aggregate of $2.4 million and bearing interest at per annum rates ranging from 1.68% to 2.55%. Of the Frazier Notes, $1.9 million were issued in 2018 and $0.5 million were issued in April 2019. Due to certain embedded features within the Frazier Notes, the Company elected to account for these notes and all their embedded features under the fair value option. The Company recorded changes in the fair value of the Frazier Notes in the statements of operations until May 2019, when the Frazier Notes and related accrued interest were exchanged, at their then fair value of $2.4 million, for the convertible promissory notes issued by the Company in May 2019 (the “May 2019 Notes”). For the year ended December 31, 2019 , the Company recognized $50,000 of other income in the statements of operations related to decreases in the fair value of the Frazier Notes. For the year ended December 31, 2019, the Company recognized $15,000 of interest expense in connection with the Frazier Notes. The Company did not incur any such expenses during the year ended December 31, 2020 as the Frazier Notes were exchanged in May 2019. May 2019 Convertible Note Financing In May 2019, the Company entered into a note purchase agreement under which it issued the unsecured May 2019 Notes for an aggregate of $90.3 million, resulting in gross proceeds to the Company of $87.8 million in cash and $2.4 million related to the exchange of the Frazier Notes and related accrued interest for the May 2019 Notes. Including the conversion of the Frazier Notes, Frazier purchased $20.0 million of the May 2019 Notes. The May 2019 Notes bore interest at a rate of 6% per annum and were subordinated to borrowings under the Company’s loan and security agreement (see Note 7). Due to certain embedded features within the May 2019 Notes, the Company elected to account for these notes and all their embedded features under the fair value option. The outstanding principal and accrued interest of the May 2019 Notes automatically converted into 6,107,918 shares of common stock immediately prior to the completion of the IPO on October 29, 2019.

Lease Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Lease Commitments	6. Lease Commitments As of December 31, 2020, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of 4.3 years and 4.7 years, respectively. The total rent expense for the years ended December 31, 2020 and 2019 was approximately $0.5 million and $51,000, respectively. The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2020: As of December 31, 2020 Assets: Operating lease right-of-use assets $ 2,373 Total right-of-use assets 2,373 Liabilities: Operating lease liabilities, current 474 Operating lease liabilities, non-current 1,557 Total operating lease liabilities $ 2,031 As of December 31, 2020, the future minimum annual lease payments under the operating leases were as follows (in thousands): 2021 $ 490 2022 503 2023 516 2024 529 2025 342 Total minimum lease payments 2,380 Less: amount representing interest (349 ) Present value of operating lease liabilities 2,031 Less: operating lease liabilities, current (474 ) Operating lease liabilities $ 1,557 Weighted-average remaining lease term (in years) 4.56 Weighted-average incremental borrowing rate 7.25 % Operating cash flows for the year ended December 31, 2020 included $0.9 million in cash payments for operating leases, $0.6 million of which were prepaid lease payments.

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	7. Debt Total debt consists of the following (in thousands): December 31, 2020 Long-term debt, current portion $ 7,353 Long-term debt, non-current portion 42,647 Unamortized debt discount (3,013 ) Total debt, net of debt discount $ 46,987 On May 14, 2019, the Company entered into a loan and security agreement (the “Loan Agreement”, and all amounts borrowed thereunder the “Term Loans”) with Silicon Valley Bank (“SVB”), as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. (“WestRiver”). The Company borrowed $25.0 million (“Term Loan A”) at the inception of the Loan Agreement and an additional $25.0 million (“Term Loan B”) on March 16, 2020. The Term Loans bear interest at a floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% (5% at December 31, 2020) or 7.25%. Under the original Loan Agreement, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment (the “Amendment”) to the Loan Agreement. Pursuant to the Amendment, the interest-only payment period was extended either (i) until December 31, 2021, if the Company receives positive data from its Phase 3 clinical trial in H. pylori sufficient to file a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”); or (ii) until November 30, 2022, if the Company receives positive data from its Phase 3 clinical trials in both indications for vonoprazan sufficient to file NDAs with the FDA; provided, in each case, that the Company had drawn down an additional $25.0 million, Term Loan B, pursuant to the Loan Agreement. The Company may elect to prepay all or a portion of the Term Loans prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts may be borrowed again. The borrowings under the Loan Agreement are collateralized by substantially all of the Company’s assets, excluding intellectual property and certain other assets. The Loan Agreement includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants include, among others, limitations on the Company’s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The Loan Agreement also contains customary events of default, including bankruptcy, the failure to make payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 4.00% above the rate effective immediately before the event of default and may be declared immediately due and payable by SVB, as collateral agent. As of December 31, 2020, the Company was in compliance with all applicable covenants under the Loan Agreement. In connection with the Loan Agreement, the Company issued the Lender Warrants to purchase stock of the Company, which expire ten years from the date of issuance. Upon completion of the IPO in 2019, the Lender Warrants became exercisable for 16,446 shares of common stock. The Lender Warrants included a put option pursuant to which, in the event that the Company did not draw down Term Loan B on or before March 31, 2020, the warrant holders could have required that the Company repurchase the warrants for a total aggregate repurchase price of $0.5 million. Upon the Term Loan B draw in March 2020, the Lender Warrants became exercisable and the put option related to the Lender Warrants expired. Accordingly, the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $0.3 million to additional paid-in-capital. The initial $0.4 million fair value of the Lender Warrants, the $4.1 million final payment fee and $0.2 million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loans. During the years ended December 31, 2020 and 2019, the Company recognized $4.6 million and $1.6 million, respectively, of interest expense, including amortization of the debt discount, in connection with the Loan Agreement. As of December 31, 2020, the Company had outstanding Term Loans of $50.0 million and accrued interest of $0.3 million. Future minimum principal and interest payments under the Term Loans, including the final payment fee, as of December 31, 2020 (at the December 31, 2020 interest rate) are as follows (in thousands): Year ending December 31: 2021 $ 10,938 2022 20,187 2023 18,889 2024 11,614 Total principal and interest payments 61,628 Less interest and final payment fee (11,628 ) Total term loan borrowings $ 50,000

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Common Stock In March 2019, subsequent to the Merger, the Company sold 1,491,072 shares of the Company’s common stock to Frazier. In March 2019, the founders granted the Company a repurchase right for the 3,373,408 shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder’s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for 843,352 shares in March 2019 and the repurchase right for the remaining 2,530,056 shares lapses in equal monthly amounts over the following 48-month period ending in March 2023. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2020, 1,423,153 shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented. In May 2019, the Company issued Takeda 1,084,000 shares of common stock in connection with the Takeda License. For the period from January 1, 2019 to May 6, 2019, the Company issued 2,524,852 shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $1,000. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to 25% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to 1/48th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased 17,560 shares at the original purchase price for an aggregate purchase price of $5.20. As of December 31, 2020, 1,323,606 shares remain available for repurchase by the Company and the associated repurchase liability was not significant. On October 29, 2019, upon completion of the IPO, the Company sold 10,997,630 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares at a public offering price of $19.00 per share In November 2020, the Company filed a shelf registration statement (No. 333-250014) on Form S-3 (the "S-3") which was declared effective on November 17, 2020. Under the S-3, the Company may sell up to a total of $500 million of its securities. In connection with the S-3, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $125.0 million through the Sales Agent (the “ATM Offering”). Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold. No shares were sold under the ATM Offering as of December 31, 2020. On December 16, 2020, the Company completed an underwritten public offering (the “Underwriting Agreement”), in which it sold 2,250,000 shares of its common stock at a price of $42.00 per share for total gross proceeds of $94.5 million. The purchase price after deducting underwriting discounts and commissions was $39.48 per share, which generated net proceeds of $88.8 million. The Company incurred an additional $0.2 million of offering expenses in connection with the Underwriting Agreement, and the ending net proceeds were $88.6 million. The shares were sold under the S-3. In addition, under the terms of the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase up to 337,500 additional shares of Common Stock at the public offering price, less underwriting discounts and commissions. The 30-day option expired with no additional shares purchased. A summary of the Company’s unvested shares is as follows: Balance at December 31, 2019 4,236,248 Share vesting (1,489,489 ) Balance at December 31, 2020 2,746,759 For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they vest. Common stock reserved for future issuance consists of the following: December 31, 2020 Common stock warrants 7,604,446 Stock options and performance-based awards outstanding 2,948,742 Shares available for issuance under the 2019 Incentive Plan 2,262,103 Shares available for issuance under the ESPP Plan 559,645 Balance at December 31, 2020 13,374,936 Preferred Stock The Company is authorized to issue up to 40 million shares of preferred stock. As of December 31, 2020, and December 31, 2019, there were no shares of preferred stock issued or outstanding. Equity Incentive Plan The Company’s 2019 Equity Incentive Plan (the “Existing Incentive Plan”) provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had 2,231,739 shares of common stock authorized for issuance under the Existing Incentive Plan, of which, 1,400,528 stock options and 16,260 restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan (the “2019 Plan”) in October 2019, no further shares are available for issuance under the Existing Incentive Plan. 2019 Incentive Award Plan In October 2019, the board of directors adopted, and the Company’s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. The Company initially had 2,700,000 shares of common stock available for issuance under the 2019 Plan, of which, 1,376,477 stock options were granted and 220,000 performance-based units were granted during the year ended December 31, 2020. As of December 31, 2020, 2,262,103 shares remain available for issuance, which includes the annual increase of 1,158,580 shares that were authorized on January 1, 2020. An additional 1,250,511 shares were authorized on January 1, 2021. Performance-based Units During 2020, the Company granted 220,000 performance-based stock units (“PSU”) whereby vesting depends upon the approval by the U.S. Food and Drug Administration (“FDA”) of vonoprazan for H. pylori Number of Stock Units Weighted- Average Grant Date Fair Value Per Share Unvested balance at December 31, 2019 — $ — Granted 220,000 32.48 Vested — — Forfeited — — Unvested balance at December 31, 2020 220,000 $ 32.48 As of December 31, 2020 there was approximately $7.1 million of related unrecognized compensation cost, which will begin to be recognized when vesting is probable. Employee Stock Purchase Plan In October 2019, the board of directors adopted, and the Company’s stockholders approved, the Employee Stock Purchase Plan (the “ESPP”), which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a participant’s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of 270,000 shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2020, 559,645 shares of common stock remain available for issuance, which includes the annual increase of 289,645 shares that were authorized on January 1, 2020. An additional 312,628 shares were authorized on January 1, 2021. The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $0.3 million for the year ended December 31, 2020. The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows: Years Ended December 31, 2020 2019 Assumptions: Expected term (in years) 1.00 — Expected volatility 76.25 % — Risk free interest rate 0.15 % — Dividend yield — — The estimated weighted-average fair value of ESPP awards during 2020 was $13.66. As of December 31, 2020, the total unrecognized compensation expense related to the ESPP was $0.2 million, which is expected to be recognized over a weighted-average period of approximately 0.6 years. As of December 31, 2020, no shares of common stock had been issued under the ESPP. Stock Options The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company’s stock options for employees was determined utilizing the “simplified” method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 1,400,528 $ 9.10 9.69 $ 30,874 Options granted 1,376,477 33.55 Options exercised and shares vested (48,263 ) 13.04 Options cancelled — — Balance at December 31, 2020 2,728,742 $ 21.36 9.10 $ 34,432 Options exercisable as of December 31, 2020 345,043 8.98 8.68 8,362 Options vested and expected to vest as of December 31, 2020 2,728,742 21.36 9.10 34,432 The aggregate intrinsic value of options exercisable as of December 31, 2020 is calculated as the difference between the exercise price of the underlying options and the closing market price of the Company’s common stock on that date, which was $33.22 per share. The aggregate intrinsic value of options exercised during the year ended December 31, 2020 was approximately $1.5 million, determined as of the date of exercise. There were no option exercises during the year ended December 31, 2019. The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2020 was $19.59. As of December 31, 2020, the Company had $28.2 million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of 3.8 years. The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows: Years Ended December 31, 2020 2019 Assumptions: Expected term (in years) 6.06 6.07 Expected volatility 65.07 % 60.17 % Risk free interest rate 0.51 % 1.58 % Dividend yield — — Stock-Based Compensation Expense Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands): Years Ended December 31, 2020 2019 Research and development expense $ 1,450 $ 106 General and administrative expense 4,390 300 Total $ 5,840 $ 406

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes For the years ended December 31, 2020 and 2019, the Company did not record a provision for income taxes due to a full valuation against its deferred taxes. A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands): Years Ended December 31, 2020 2019 Income taxes computed at the statutory rate $ (27,105 ) $ (53,578 ) Permanent items 291 552 Change in fair value of warrants and convertible debt (20 ) 30,622 Research and development credit (3,047 ) (697 ) Change in valuation allowance 29,949 23,046 Other (68 ) 55 Provision (benefit) for income taxes $ — $ — Significant components of the Company’s net deferred tax assets are as follows (in thousands): Years Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 33,162 $ 6,322 Research credits 3,744 697 Intangible assets 14,929 16,050 Other 1,914 428 Gross deferred tax assets 53,749 23,497 Less valuation allowance (53,250 ) (23,301 ) Deferred tax assets, net of valuation allowance 499 196 Deferred tax liabilities: Other (499 ) (196 ) Net deferred tax assets $ — $ — Based upon the Company’s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2020 and 2019. As of December 31, 2020 and 2019, the Company had federal net operating loss carryforwards of approximately $157.8 million and $30.1 million, respectively, which are carried over indefinitely. As of December 31, 2020, the Company has available federal research and development credits of $4.7 million which begin to expire in 2038. The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2020. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete. Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company’s effective tax rate. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company's gross unrecognized tax benefits: Years Ended December 31, 2020 2019 Beginning balance $ 176 $ — Increases related to current year tax positions 762 176 Ending balance $ 938 $ 176 As of December 31, 2020, the Company has gross unrecognized tax benefits of $0.9 million, none of which would affect the effective tax rate due to a full valuation allowance. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company has no accrual for interest or penalties on its balance sheet at December 31, 2020 and has not recognized interest or penalties in its statement of operations for the year ended December 31, 2020. The Company is subject to taxation in the United States and California. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.

401(k) Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
401(k) Plan	10. 401(k) Plan The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company’s contributions to the plan are discretionary. During the year ended December 31, 2020, the Company incurred $0.3 million of expense related to employer contributions. As of December 31, 2020 the Company had $0.3 million of 401(k) contribution liabilities, which was based on a 75% match of employees’ annual contributions. In January 2021, the Board of Directors approved the discretionary match, which was settled by contributing 8,356 shares.

Quarterly Financial Information

Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited)	11 . The following table summarizes the unaudited financial results of operations for the quarters indicated: 2020 Quarter Ended March 31, June 30, September 30, December 31, (unaudited) Operating expenses: Research and development $ 15,865 $ 14,859 $ 25,770 $ 41,654 General and administrative 4,510 5,162 7,060 10,785 Total operating expenses 20,375 20,021 32,830 52,439 Loss from operations (20,375 ) (20,021 ) (32,830 ) (52,439 ) Total other income (expense) 234 (1,080 ) (1,275 ) (1,282 ) Net loss $ (20,141 ) $ (21,101 ) $ (34,105 ) $ (53,721 ) Net loss per share, basic and diluted $ (0.62 ) $ (0.64 ) $ (1.02 ) $ (1.58 ) Weighted-average shares of common stock outstanding, basic and diluted 32,470,402 32,997,099 33,366,237 34,060,291 2019 Quarter Ended March 31, June 30, September 30, December 31, (unaudited) Operating expenses: Research and development $ 429 $ 2,772 $ 4,469 $ 12,704 In-process research and development — 78,897 — — General and administrative 797 1,345 1,813 2,989 Total operating expenses 1,226 83,014 6,282 15,693 Loss from operations (1,226 ) (83,014 ) (6,282 ) (15,693 ) Total other income (expense) (25 ) (4,748 ) (61,830 ) (82,313 ) Net loss $ (1,251 ) $ (87,762 ) $ (68,112 ) $ (98,006 ) Net loss per share, basic and diluted $ (0.19 ) $ (13.11 ) $ (9.30 ) $ (3.97 ) Weighted-average shares of common stock outstanding, basic and diluted 6,585,503 6,694,682 7,326,090 24,706,661

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events In March 2021, the Company entered into the Second Amendment (the “Amendment”) to the Loan Agreement which further amended certain terms of the Loan Agreement, dated as of May 14, 2019. The Amendment extends the current interest-only period of the Loan Agreement from May 31, 2021 to July 31, 2021. After July 31, 2021, the interest-only period will be extended either (i) until December 31, 2021, if the Company receives positive data from its Phase 3 clinical trial in H. pylori infection sufficient to file an NDA with the FDA; or (ii) until November 30, 2022, if the Company receives positive data from its Phase 3 clinical trials in both indications for vonoprazan sufficient to file an NDA with the FDA. Subsequent to the interest-only period, the Term Loans will be payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of May 1, 2024.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The accompanying financial statements include the accounts of the Company (the receiving entity) and YamadaCo, prior to the Merger. The Company and YamadaCo were entities under the common control of Frazier Life Sciences IX, L.P. (“Frazier”) as a result of, among other things, Frazier’s; (i) ownership of a majority of the outstanding capital stock of both companies, (ii) financing of both companies, (iii) control of the board of directors of both companies, and (iv) management of both companies. Both the Company and YamadaCo were formed for the purpose of identifying potential assets around which to form an operating company. As the merged entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company and YamadaCo as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions have been eliminated.
Liquidity and Capital Resources	Liquidity and Capital Resources From inception to December 31, 2020, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2020, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, and the sale of 10,997,630 shares of common stock for net proceeds of approximately $191.5 million in its 2019 IPO. Additionally, in December 2020, the Company raised net proceeds of $88.6 million from the sale of 2,250,000 shares of common stock at a public offering price of $39.48 per share after deducting underwriting discounts and commissions, and an additional $0.2 million in offering costs. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, (if needed), that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.
Fair Value Option	Fair Value Option As permitted under Accounting Standards Codification (“ASC”) 825, Financial Instruments
Fair Value Measurements	Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities and convertible promissory notes are recorded at fair value on a recurring basis. The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Liabilities measured at fair value on a recurring basis are as follows (in thousands): The warrant liabilities consist of warrants (the “Lender Warrants”) issued in connection with a loan and security agreement (the “Loan Agreement”) for commercial bank debt (see Note 7). The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands): Warrant Liabilities Convertible Promissory Notes Balance at December 31, 2018 $ — $ 1,950 Issuance of convertible promissory notes — 90,750 Exchange of convertible promissory notes (Note 4) — (2,399 ) Issuance of warrants 48,313 — Change in fair value 96,272 49,546 Reclassification of Takeda Warrants into Equity (Note 4) (144,172 ) — Conversion of May 2019 Notes into common shares upon IPO (Note 5) — (139,847 ) Balance at December 31, 2019 413 — Change in fair value (95 ) — Reclassification of Lender Warrants into equity (Note 7) (318 ) — Balance at December 31, 2020 $ — $ —
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Property, Plant, and Equipment, Net	Property, Plant, and Equipment, Net Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over two to three years. Furniture and fixtures are depreciated over three years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through December 31, 2020.
Leases	Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.
Research and Development Expenses and Accruals	Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials. The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
In-Process Research and Development	In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss was the same as its reported net loss for all periods presented.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.
Net Loss Per Share	Net Loss Per Share For the year ended December 31, 2019, the net loss per share was recast to include in the numerator the net losses of both the Company and YamadaCo and include in the denominator the weighted-average outstanding shares of both the Company and YamadaCo. Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included 7,588,000 shares of common stock under its warrant (the “Takeda Warrant”) issued to Takeda Pharmaceutical Company Limited (“Takeda”) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company’s IPO because the Takeda Warrant is exercisable for little consideration. For the years ended December 31, 2020 and 2019, the Company has excluded weighted-average unvested shares of 3,424,676 and 3,593,034, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options, warrants and convertible promissory notes. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize, as an allowance, its estimate of expected credit losses. ASU 2016-13 is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance effective January 1, 2020, and the adoption did not have a material impact on the Company's financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, modifies and adds disclosure requirements on fair value measurements. The standard is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance effective January 1, 2020, and the adoption did not have a material impact on the Company’s financial statements. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company does not expect the adoption of ASU 2019-12 will have a significant impact on its financial statements.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Reconciliation of Liabilities Measured at Fair Value	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands): Warrant Liabilities Convertible Promissory Notes Balance at December 31, 2018 $ — $ 1,950 Issuance of convertible promissory notes — 90,750 Exchange of convertible promissory notes (Note 4) — (2,399 ) Issuance of warrants 48,313 — Change in fair value 96,272 49,546 Reclassification of Takeda Warrants into Equity (Note 4) (144,172 ) — Conversion of May 2019 Notes into common shares upon IPO (Note 5) — (139,847 ) Balance at December 31, 2019 413 — Change in fair value (95 ) — Reclassification of Lender Warrants into equity (Note 7) (318 ) — Balance at December 31, 2020 $ — $ —

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net, consist of the following (in thousands): Years Ended December 31, 2020 2019 Computer equipment and software $ 516 $ 152 Furniture and fixtures 747 306 Leasehold improvements 54 13 1,317 471 Less: accumulated depreciation (331 ) (8 ) Total property, plant and equipment, net $ 986 $ 463
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): Years Ended December 31, 2020 2019 Accrued research and development expenses $ 4,864 $ 384 Accrued compensation expenses 4,587 1,052 Accrued professional & consulting expenses 1,123 478 Accrued other 32 405 Total accrued expenses $ 10,606 $ 2,319

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Summary of Supplemental Balance Sheet Information Related to the Operating Leases	The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2020: As of December 31, 2020 Assets: Operating lease right-of-use assets $ 2,373 Total right-of-use assets 2,373 Liabilities: Operating lease liabilities, current 474 Operating lease liabilities, non-current 1,557 Total operating lease liabilities $ 2,031
Summary of Future Minimum Lease Payments Under Operating Leases	As of December 31, 2020, the future minimum annual lease payments under the operating leases were as follows (in thousands): 2021 $ 490 2022 503 2023 516 2024 529 2025 342 Total minimum lease payments 2,380 Less: amount representing interest (349 ) Present value of operating lease liabilities 2,031 Less: operating lease liabilities, current (474 ) Operating lease liabilities $ 1,557 Weighted-average remaining lease term (in years) 4.56 Weighted-average incremental borrowing rate 7.25 %

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Total Debt	Total debt consists of the following (in thousands): December 31, 2020 Long-term debt, current portion $ 7,353 Long-term debt, non-current portion 42,647 Unamortized debt discount (3,013 ) Total debt, net of debt discount $ 46,987
Schedule of Future Minimum Principal and Interest Payments Under Term Loans	Future minimum principal and interest payments under the Term Loans, including the final payment fee, as of December 31, 2020 (at the December 31, 2020 interest rate) are as follows (in thousands): Year ending December 31: 2021 $ 10,938 2022 20,187 2023 18,889 2024 11,614 Total principal and interest payments 61,628 Less interest and final payment fee (11,628 ) Total term loan borrowings $ 50,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Unvested Shares	A summary of the Company’s unvested shares is as follows: Balance at December 31, 2019 4,236,248 Share vesting (1,489,489 ) Balance at December 31, 2020 2,746,759
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consists of the following: December 31, 2020 Common stock warrants 7,604,446 Stock options and performance-based awards outstanding 2,948,742 Shares available for issuance under the 2019 Incentive Plan 2,262,103 Shares available for issuance under the ESPP Plan 559,645 Balance at December 31, 2020 13,374,936
Summary of PSU Activity Under the 2019 Incentive Award Plan	The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2020 Number of Stock Units Weighted- Average Grant Date Fair Value Per Share Unvested balance at December 31, 2019 — $ — Granted 220,000 32.48 Vested — — Forfeited — — Unvested balance at December 31, 2020 220,000 $ 32.48
Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards	The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows: Years Ended December 31, 2020 2019 Assumptions: Expected term (in years) 6.06 6.07 Expected volatility 65.07 % 60.17 % Risk free interest rate 0.51 % 1.58 % Dividend yield — —
Summary of Stock Option Activity	A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 1,400,528 $ 9.10 9.69 $ 30,874 Options granted 1,376,477 33.55 Options exercised and shares vested (48,263 ) 13.04 Options cancelled — — Balance at December 31, 2020 2,728,742 $ 21.36 9.10 $ 34,432 Options exercisable as of December 31, 2020 345,043 8.98 8.68 8,362 Options vested and expected to vest as of December 31, 2020 2,728,742 21.36 9.10 34,432
Summary of Stock-Based Compensation Expense	Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands): Years Ended December 31, 2020 2019 Research and development expense $ 1,450 $ 106 General and administrative expense 4,390 300 Total $ 5,840 $ 406
Employee Stock Purchase Plan
Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards	The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows Years Ended December 31, 2020 2019 Assumptions: Expected term (in years) 1.00 — Expected volatility 76.25 % — Risk free interest rate 0.15 % — Dividend yield — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate	A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands): Years Ended December 31, 2020 2019 Income taxes computed at the statutory rate $ (27,105 ) $ (53,578 ) Permanent items 291 552 Change in fair value of warrants and convertible debt (20 ) 30,622 Research and development credit (3,047 ) (697 ) Change in valuation allowance 29,949 23,046 Other (68 ) 55 Provision (benefit) for income taxes $ — $ —
Components of Deferred Tax Assets	Significant components of the Company’s net deferred tax assets are as follows (in thousands): Years Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 33,162 $ 6,322 Research credits 3,744 697 Intangible assets 14,929 16,050 Other 1,914 428 Gross deferred tax assets 53,749 23,497 Less valuation allowance (53,250 ) (23,301 ) Deferred tax assets, net of valuation allowance 499 196 Deferred tax liabilities: Other (499 ) (196 ) Net deferred tax assets $ — $ —
Summary of Activity Related to Gross Unrecognized Benefits	The following table summarizes the activity related to the Company's gross unrecognized tax benefits: Years Ended December 31, 2020 2019 Beginning balance $ 176 $ — Increases related to current year tax positions 762 176 Ending balance $ 938 $ 176

Quarterly Financial Informati_2

Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information (unaudited)	The following table summarizes the unaudited financial results of operations for the quarters indicated: 2020 Quarter Ended March 31, June 30, September 30, December 31, (unaudited) Operating expenses: Research and development $ 15,865 $ 14,859 $ 25,770 $ 41,654 General and administrative 4,510 5,162 7,060 10,785 Total operating expenses 20,375 20,021 32,830 52,439 Loss from operations (20,375 ) (20,021 ) (32,830 ) (52,439 ) Total other income (expense) 234 (1,080 ) (1,275 ) (1,282 ) Net loss $ (20,141 ) $ (21,101 ) $ (34,105 ) $ (53,721 ) Net loss per share, basic and diluted $ (0.62 ) $ (0.64 ) $ (1.02 ) $ (1.58 ) Weighted-average shares of common stock outstanding, basic and diluted 32,470,402 32,997,099 33,366,237 34,060,291 2019 Quarter Ended March 31, June 30, September 30, December 31, (unaudited) Operating expenses: Research and development $ 429 $ 2,772 $ 4,469 $ 12,704 In-process research and development — 78,897 — — General and administrative 797 1,345 1,813 2,989 Total operating expenses 1,226 83,014 6,282 15,693 Loss from operations (1,226 ) (83,014 ) (6,282 ) (15,693 ) Total other income (expense) (25 ) (4,748 ) (61,830 ) (82,313 ) Net loss $ (1,251 ) $ (87,762 ) $ (68,112 ) $ (98,006 ) Net loss per share, basic and diluted $ (0.19 ) $ (13.11 ) $ (9.30 ) $ (3.97 ) Weighted-average shares of common stock outstanding, basic and diluted 6,585,503 6,694,682 7,326,090 24,706,661

Organization, Basis of Presen_4

Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	Dec. 16, 2020USD ($)shares	Oct. 29, 2019USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	May 31, 2019shares	May 06, 2019shares	Dec. 31, 2020USD ($)Segment$ / sharesshares	Dec. 31, 2019USD ($)shares
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proceeds from Initial Public Offering (IPO)							$ 191,472,000
Fair value liabilities, level 1 to level 2 transfers, amount			$ 0			$ 0	0
Fair value liabilities, level 2 to level 1 transfers, amount			$ 0			0	0
Fair value liability, transfers into level 3						0	0
Fair value liability, transfers out of level 3						0	0
Conversion of Lender Warrants into equity						318,000	$ 144,172,000
Impairment losses						$ 0
Number of operating segment | Segment						1
Accounting Standards Update 2016-13
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, Accounting Standards Update, adopted [true false]			true			true
Change in accounting principle, Accounting Standards Update, Adoption date			Jan. 1, 2020			Jan. 1, 2020
Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]			true			true
Accounting Standards Update 2018-13
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, Accounting Standards Update, adopted [true false]			true			true
Change in accounting principle, Accounting Standards Update, Adoption date			Jan. 1, 2020			Jan. 1, 2020
Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]			true			true
Unvested Shares
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Weighted-average unvested shares | shares						3,424,676	3,593,034
Furniture and Fixtures
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life						3 years
Minimum | Computer Equipment and Related Software
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life						2 years
Maximum | Computer Equipment and Related Software
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life						3 years
Lender Warrants
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Expected cash dividend yield						0.00%
Takeda Warrant | Takeda License | Takeda
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Shares of common stock included in calculation of basic weighted-average common shares | shares							7,588,000
Fair Value, Recurring
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Financial assets fair value disclosure			$ 0			$ 0
Fair Value, Nonrecurring
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Non-financial assets fair value disclosure			0			0
Non-financial liabilities fair value disclosure			$ 0			0
Common Stock
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares					2,524,852
Common Stock | Takeda License
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares				1,084,000			1,084,000
Additional Paid-in Capital
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Conversion of Lender Warrants into equity						318,000	$ 144,172,000
Additional Paid-in Capital | Lender Warrants
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Conversion of Lender Warrants into equity						$ 400,000
IPO | Common Stock
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares		10,997,630	2,250,000				10,997,630
Proceeds from Initial Public Offering (IPO)		$ 191,500,000
Public offering price per share | $ / shares			$ 39.48			$ 39.48
Offering costs			$ 200,000			$ 200,000
Underwritten Public Offering
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares	2,250,000
Proceeds from Initial Public Offering (IPO)	$ 88,600,000		$ 88,600,000
Underwritten Public Offering | Common Stock
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares		1,434,473				2,250,000

Organization, Basis of Presen_5

Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details) - Significant Unobservable Inputs (Level 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warrant Liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning Balance	$ 413
Issuance of warrants		$ 48,313
Change in fair value	(95)	96,272
Ending Balance		413
Takeda Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Reclassification of Warrants into Equity		(144,172)
Lender Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Reclassification of Warrants into Equity	$ (318)
Convertible Promissory Notes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning Balance		1,950
Issuance of convertible promissory notes		90,750
Exchange of convertible promissory notes (Note 4)		(2,399)
Change in fair value		49,546
Conversion of May 2019 Notes into common shares upon IPO (Note 5)		$ (139,847)

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,317	$ 471
Less: accumulated depreciation	(331)	(8)
Total property, plant and equipment, net	986	463
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	516	152
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	747	306
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 54	$ 13

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Depreciation expense	$ 300,000	$ 8,000
Disposal of property, plant or equipment	$ 0	$ 0

Balance Sheet Details - Sched_2

Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Accrued research and development expenses	$ 4,864	$ 384
Accrued compensation expenses	4,587	1,052
Accrued professional & consulting expenses	1,123	478
Accrued other	32	405
Total accrued expenses	$ 10,606	$ 2,319

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	May 05, 2020	Dec. 31, 2020	Dec. 31, 2019
Commercial Supply Agreement
Related Party Transaction [Line Items]
Agreement extends period for termination	2 years
Minimum purchase obligation		$ 2,200,000
Drug Product | Commercial Supply Agreement
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses		200,000
Expense related to services		300,000
Frazier
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses		35,000	$ 100,000
Shared operating expenses		200,000	400,000
PCI Pharma Services | Clinical Manufacturing Services
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses		400,000	300,000
Expense related to services		2,300,000	1,100,000
Mountain Field LLC
Related Party Transaction [Line Items]
Shared operating expenses		0	100,000
Takeda | Takeda License
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses		22,000	100,000
Expense related to services		0	$ 100,000
Takeda | Temporary Services Agreement
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses		200,000
Expense related to services		$ 200,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Oct. 11, 2019	May 07, 2019	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies [Line Items]
Common stock fair value			$ 3,000	$ 2,000
Common stock, shares issued			31,262,769	28,964,506
Common stock, shares authorized	50,000,000		400,000,000	400,000,000
Fair value adjustment of warrants			$ (95,000)	$ 96,272,000
Expenses incurred related to purchase commitments			0
Minimum
Commitments And Contingencies [Line Items]
Purchase obligation in the first 24-month period			$ 3,800,000
Takeda License | Takeda
Commitments And Contingencies [Line Items]
License agreement description			The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents.
Agreement expiration term from date of first commercial sale		15 years
Cash consideration paid for license		$ 25,000,000
Common stock fair value		$ 5,900,000
Common stock, shares issued		1,084,000
Warrants exercise price		$ 0.00004613
Initial fair value of warrants		$ 47,900,000
Additional warrant issued		0
Maximum amount payable in sales milestones upon achievement of specified levels of product sales		$ 250,000,000
Transaction costs		$ 100,000
Warrants expiration date		May 7, 2029
Fair value adjustment of warrants	$ 144,200,000
Takeda License | Takeda | Common Stock
Commitments And Contingencies [Line Items]
Warrants issued to purchase shares		7,588,000

Convertible Promissory Notes -

Convertible Promissory Notes - Additional Information (Details) - USD ($)	Oct. 29, 2019	May 31, 2019	Apr. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Frazier Convertible Note Financing
Debt Instrument [Line Items]
Aggregate amount of debt instrument			$ 2,400,000
Debt instrument issued, amount			$ 500,000			$ 1,900,000
Interest expense				$ 0	$ 15,000
Frazier Convertible Note Financing | Other Income (Expense)
Debt Instrument [Line Items]
Increases (decreases) in fair value of debt instrument					$ (50,000)
Frazier Convertible Note Financing | Minimum
Debt Instrument [Line Items]
Debt instrument, interest rate percentage			1.68%
Frazier Convertible Note Financing | Maximum
Debt Instrument [Line Items]
Debt instrument, interest rate percentage			2.55%
May 2019 Convertible Note Financing
Debt Instrument [Line Items]
Aggregate amount of debt instrument		$ 90,300,000
Debt instrument, interest rate percentage		6.00%
Fair value of convertible promissory notes		$ 2,400,000
Proceeds from issuance of unsecured debt		87,800,000
May 2019 Convertible Note Financing | Common Stock
Debt Instrument [Line Items]
Debt instrument conversion, shares issued	6,107,918
May 2019 Convertible Note Financing | Frazier
Debt Instrument [Line Items]
Debt instrument purchased amount		$ 20,000,000

Lease Commitments - Additional

Lease Commitments - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)Option	Dec. 31, 2019USD ($)
Lessee Lease Description [Line Items]
Operating leases, rent expense	$ 500,000	$ 51,000
Cash payments for operating lease costs	900,000
Prepaid Lease Payments
Lessee Lease Description [Line Items]
Cash payments for operating lease costs	$ 600,000
Buffalo Grove, Illinois
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	4 years 3 months 18 days
Operating lease number of option to extend | Option	1
Operating lease, option to extend description	Both operating leases contain an option to extend the term for one additional five-year period
Lessee, operating lease, existence of option to terminate	true
Operating lease, renewal term	5 years
Florham Park, New Jersey
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	4 years 8 months 12 days
Operating lease number of option to extend | Option	1
Operating lease, option to extend description	Both operating leases contain an option to extend the term for one additional five-year period
Lessee, operating lease, existence of option to terminate	true
Operating lease, renewal term	5 years

Lease Commitments - Summary of

Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets:
Operating lease right-of-use assets	$ 2,373	$ 933
Liabilities:
Operating lease liabilities, current	474	161
Operating lease liabilities, non-current	1,557	$ 635
Total operating lease liabilities	$ 2,031

Lease Commitments - Summary o_2

Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 490
2022	503
2023	516
2024	529
2025	342
Total minimum lease payments	2,380
Less: amount representing interest	(349)
Total operating lease liabilities	2,031
Less: operating lease liabilities, current	(474)	$ (161)
Operating lease liabilities	$ 1,557	$ 635
Weighted-average remaining lease term (in years)	4 years 6 months 21 days
Weighted-average incremental borrowing rate	7.25%

Debt - Schedule of Total Debt (

Debt - Schedule of Total Debt (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt Disclosure [Abstract]
Long-term debt, current portion	$ 7,353
Long-term debt, non-current portion	42,647
Unamortized debt discount	(3,013)
Total debt, net of debt discount	$ 46,987

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	May 14, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 16, 2020	Mar. 11, 2020
Debt Instrument [Line Items]
Long-term debt outstanding		$ 50,000
Loan Agreement
Debt Instrument [Line Items]
Interest bearing rate upon customary events	4.00%
Warrants exercisable shares of common stock	16,446
Warrants expire term	10 years
Aggregate repurchase price of warrants	$ 500
Adjustments to additional paid-in-capital, warrants issued		300
Fair value of warrant liabilities	400
Interest expense		$ 4,600	$ 1,600
Term Loans
Debt Instrument [Line Items]
Aggregate amount of debt instrument	$ 25,000
Debt instrument, additional borrowing capacity amount				$ 25,000	$ 25,000
Debt instrument, interest rate percentage	7.25%	5.00%
Debt instrument, description		Under the original Loan Agreement, the monthly payments consisted of interest-only through May 31, 2021.
Debt instrument, maturity date	May 1, 2024
Debt instrument, final payment fee percentage	8.25%
Debt instrument, final payment fee	$ 4,100
Debt issuance costs	$ 200
Long-term debt outstanding		$ 50,000
Accrued interest		$ 300
Term Loans | Maximum
Debt Instrument [Line Items]
Debt instrument, prepayment fee percentage of outstanding principal amount	2.00%
Term Loans | Prime Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.75%

Debt - Schedule of Future Minim

Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt Disclosure [Abstract]
2021	$ 10,938
2022	20,187
2023	18,889
2024	11,614
Total principal and interest payments	61,628
Less interest and final payment fee	(11,628)
Total term loan borrowings	$ 50,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)

Jan. 01, 2021

Dec. 16, 2020

Nov. 17, 2020

Oct. 29, 2019

Dec. 31, 2020

Nov. 30, 2019

Oct. 31, 2019

May 31, 2019

Mar. 31, 2019

May 06, 2019

Dec. 31, 2020

Dec. 31, 2019

Jan. 01, 2020

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Proceeds from Initial Public Offering (IPO)

$ 191,472,000

Preferred stock, shares authorized

40,000,000

40,000,000

40,000,000

Preferred stock, shares issued

0

0

0

Preferred stock, shares outstanding

0

0

0

Stock options, granted

1,376,477

Stock-based compensation cost

$ 5,840,000

$ 406,000

Common stock initially reserved for issuance

13,374,936

13,374,936

Unrecognized stock-based compensation expense

$ 28,200,000

$ 28,200,000

Unrecognized stock-based compensation expense, weighted-average period for recognition

3 years 9 months 18 days

Dividend yield

0.00%

Closing market price of common stock

$ 33.22

Aggregate intrinsic value of stock options exercised

$ 1,500,000

Issuance of common stock from exercise of stock options, shares

0

Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Dividend yield

0.00%

2019 Equity Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock, shares authorized for issuance

2,231,739

Number of shares available for issuance

0

Stock options, granted

1,400,528

2019 Equity Incentive Plan | Restricted Stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock awards, granted

16,260

2019 Incentive Award Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock options, granted

1,376,477

Annual increase to shares available for issuance percentage of outstanding common stock

5.00%

Equity plan, description

The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. The Company initially had 2,700,000 shares of common stock available for issuance under the 2019 Plan, of which, 1,376,477 stock options were granted and 220,000 performance-based units were granted during the year ended December 31, 2020. As of December 31, 2020, 2,262,103 shares remain available for issuance, which includes the annual increase of 1,158,580 shares that were authorized on January 1, 2020. An additional 1,250,511 shares were authorized on January 1, 2021.

Number of shares remain available for issuance, annual increase

1,158,580

Common stock initially reserved for issuance

2,262,103

2,262,103

2019 Incentive Award Plan | Subsequent Event

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Additional number of shares available for issuance

1,250,511

2019 Incentive Award Plan | Performance-Based Stock Units (PSU)

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock awards, granted

220,000

Stock-based compensation cost

$ 0

Unrecognized stock-based compensation expense

$ 7,100,000

$ 7,100,000

Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of shares available for issuance

559,645

559,645

Annual increase to shares available for issuance percentage of outstanding common stock

1.00%

Equity plan, description

In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2020, 559,645 shares of common stock remain available for issuance, which includes the annual increase of 289,645 shares that were authorized on January 1, 2020. An additional 312,628 shares were authorized on January 1, 2021

Number of shares remain available for issuance, annual increase

289,645

Stock-based compensation cost

$ 300,000

Common stock initially reserved for issuance

559,645

270,000

559,645

Estimated weighted-average fair value

$ 13.66

Unrecognized stock-based compensation expense

$ 200,000

$ 200,000

Unrecognized stock-based compensation expense, weighted-average period for recognition

7 months 6 days

Dividend yield

0.00%

Employee Stock Purchase Plan | Subsequent Event

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Additional number of shares available for issuance

312,628

IPO

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Issuance of common stock

$ 191,472,000

Underwritten Public Offering

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

2,250,000

Common stock, price per share

$ 42

Proceeds from Initial Public Offering (IPO)

$ 88,600,000

$ 88,600,000

Issuance of common stock

$ 88,596,000

Proceeds from issuance initial public offering gross

$ 94,500,000

Purchase price per share after deducting underwriting discounts and commissions

$ 39.48

Net proceeds after deducting underwriters commission

$ 88,800,000

Purchase of additional offering expenses

$ 200,000

Option to purchase additional shares

337,500

Option to purchase additional shares period

30 days

Additional shares purchased, 30-day option expiration

0

At-the-Market Offering Program

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

0

Employee and Nonemployee Director

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Estimated weighted-average fair value

$ 19.59

Takeda License

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Issuance of common stock

$ 5,885,000

Open Market Sale Agreement with Jefferies LLC | Maximum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Issuance of common stock

$ 500,000,000

Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Percentage of gross sales price per share sold

3.00%

Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program | Maximum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Proceeds from issuance of shares

$ 125,000,000

Common Stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

2,524,852

Number of shares authorized to repurchase

3,373,408

Stock repurchase program, number of shares right lapse

843,352

Remaining number of shares to be repurchased

2,530,056

Stock repurchase program, period in force

48 months

Stock repurchase program expiration date

Mar. 31, 2023

Proceeds from issuance of shares

$ 1,000,000

Repurchase right lapse each month after first anniversary, shares

0.000208

Repurchases of shares

17,560

Shares aggregate repurchase price

$ 5.20

Issuance of common stock from exercise of stock options, shares

48,263

Common Stock | 2019 Incentive Award Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock, shares authorized for issuance

2,700,000

Number of shares available for issuance

2,262,103

2,262,103

Additional number of shares available for issuance

1,416,788

Common Stock | Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

0

Maximum percentage of eligible compensation contributed by participants

20.00%

Common Stock | IPO

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

10,997,630

2,250,000

10,997,630

Common stock, price per share

$ 19

Proceeds from Initial Public Offering (IPO)

$ 191,500,000

Issuance of common stock

$ 1,000

Common Stock | Underwritten Public Offering

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

1,434,473

2,250,000

Common Stock | Employees

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Remaining number of shares to be repurchased

1,323,606

1,323,606

Common Stock | First Anniversary

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Repurchase right lapse rate

25.00%

Common Stock | Takeda License

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

1,084,000

1,084,000

Common Stock | Founders

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Remaining number of shares to be repurchased

1,423,153

1,423,153

Common Stock | Frazier

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued

1,491,072

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Shares (Details)	12 Months Ended
	Dec. 31, 2020shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Balance at December 31, 2019	4,236,248
Share vesting	(1,489,489)
Balance at December 31, 2020	2,746,759

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares	Dec. 31, 2020	Oct. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)	13,374,936
Common stock warrants
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)	7,604,446
Stock Options and Performance-Based Awards Outstanding
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)	2,948,742
2019 Incentive Award Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)	2,262,103
ESPP Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)	559,645	270,000

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Balance at December 31, 2019	4,236,248
Balance at December 31, 2020	2,746,759
2019 Incentive Award Plan | Performance-Based Stock Units (PSU)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Units, Granted	220,000
Balance at December 31, 2020	220,000
Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares	$ 32.48
Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance | $ / shares	$ 32.48

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Assumptions:
Expected term (in years)	6 years 21 days	6 years 25 days
Expected volatility	65.07%	60.17%
Risk free interest rate	0.51%	1.58%
Dividend yield	0.00%
Employee Stock Purchase Plan
Assumptions:
Expected term (in years)	1 year	0 years
Expected volatility	76.25%
Risk free interest rate	0.15%
Dividend yield	0.00%

Stockholders' Equity - Summar_5

Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning Balance	1,400,528
Options Outstanding, Options granted	1,376,477
Options Outstanding, Options exercised and shares vested	(48,263)
Options Outstanding, Ending Balance	2,728,742	1,400,528
Options Outstanding, Options exercisable as of December 31, 2020	345,043
Options Outstanding, Options vested and expected to vest as of December 31, 2020	2,728,742
Weighted-Average Exercise Price, Beginning Balance	$ 9.10
Weighted-Average Exercise Price, Options granted	33.55
Weighted-Average Exercise Price, Options exercised and shares vested	13.04
Weighted-Average Exercise Price, Ending Balance	21.36	$ 9.10
Weighted-Average Exercise Price, Options exercisable as of December 31, 2020	8.98
Weighted-Average Exercise Price, Options vested and expected to vest as of December 31, 2020	$ 21.36
Weighted-Average Remaining Contractual Term	9 years 1 month 6 days	9 years 8 months 8 days
Weighted-Average Remaining Contractual Term, Options exercisable	8 years 8 months 4 days
Weighted-Average Remaining Contractual Term, Options vested and expected to vest	9 years 1 month 6 days
Aggregate Intrinsic Value, Balance	$ 34,432	$ 30,874
Aggregate Intrinsic Value, Options exercisable	8,362
Aggregate Intrinsic Value, Options vested and expected to vest	$ 34,432

Stockholders' Equity - Summar_6

Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,840	$ 406
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,450	106
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,390	$ 300

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 0	$ 0
Research and development credits	3,744,000	697,000
Gross unrecognized tax benefits	938,000	176,000
Unrecognized tax benefits that would affect effective tax rate	0
Interest or penalties related income tax	0
Accrual for interest or penalties related to income tax	0
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards which are carried over indefinitely	157,800,000	$ 30,100,000
Research and development credits	$ 4,700,000
Research and development credits expiration period	2038

Income Taxes - Reconciliation B

Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes computed at the statutory rate	$ (27,105,000)	$ (53,578,000)
Permanent items	291,000	552,000
Change in fair value of warrants and convertible debt	(20,000)	30,622,000
Research and development credit	(3,047,000)	(697,000)
Change in valuation allowance	29,949,000	23,046,000
Other	(68,000)	55,000
Provision (benefit) for income taxes	$ 0	$ 0

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 33,162	$ 6,322
Research credits	3,744	697
Intangible assets	14,929	16,050
Other	1,914	428
Gross deferred tax assets	53,749	23,497
Less valuation allowance	(53,250)	(23,301)
Deferred tax assets, net of valuation allowance	499	196
Deferred tax liabilities:
Other	$ (499)	(196)
Net deferred tax assets		$ 0

Income Taxes - Summary of Activ

Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Beginning balance	$ 176
Increases related to current year tax positions	762	$ 176
Ending balance	$ 938	$ 176

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan employer contribution expense		$ 0.3
Defined contribution plan liability		$ 0.3
Defined contribution plan, employer matching contribution, percentage		75.00%
Subsequent Event
Defined Contribution Plan Disclosure [Line Items]
Employer discretionary match number of shares settled	8,356

Schedule of Quarterly Financial

Schedule of Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 41,654	$ 25,770	$ 14,859	$ 15,865	$ 12,704	$ 4,469	$ 2,772	$ 429	$ 98,148	$ 20,374
In-process research and development							78,897			78,897
General and administrative	10,785	7,060	5,162	4,510	2,989	1,813	1,345	797	27,517	6,944
Total operating expenses	52,439	32,830	20,021	20,375	15,693	6,282	83,014	1,226	125,665	106,215
Loss from operations	(52,439)	(32,830)	(20,021)	(20,375)	(15,693)	(6,282)	(83,014)	(1,226)	(125,665)	(106,215)
Total other income (expense)	(1,282)	(1,275)	(1,080)	234	(82,313)	(61,830)	(4,748)	(25)	(3,403)	(148,916)
Net loss and comprehensive loss	$ (53,721)	$ (34,105)	$ (21,101)	$ (20,141)	$ (98,006)	$ (68,112)	$ (87,762)	$ (1,251)	$ (129,068)	$ (255,131)
Net loss per share, basic and diluted	$ (1.58)	$ (1.02)	$ (0.64)	$ (0.62)	$ (3.97)	$ (9.30)	$ (13.11)	$ (0.19)	$ (3.88)	$ (22.45)
Weighted-average shares of common stock outstanding, basic and diluted	34,060,291	33,366,237	32,997,099	32,470,402	24,706,661	7,326,090	6,694,682	6,585,503	33,228,158	11,366,916

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details)	May 14, 2019
Term Loans
Subsequent Event [Line Items]
Debt instrument, maturity date	May 1, 2024